UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per response (

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response	,,,															
1. Name and Address of Reporting Person *- AWM Investment Company, Inc.					2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
527 MAI	DISON AV	(First) ENUE, S		3. Date of Earliest Transaction (Month/Day/Year) 09/28/2015								r (give title belo			(specify belo	ow)	
(Street)				4. If Aı	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Form fil	ual or Joint/ ed by One Repo	orting Perso	n		Line)
	ORK, NY 1		(T;)										a by More than	one repor	iting reiso		
(City	7)	(State)	(Zip)		7	Γable I	- Noi	n-De	rivative	Secui	rities Ac	quired, Disp	osed of, or	Benefici	ally Ow	ned	
(Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution any	2A. Deemed Execution Date, if any Month/Day/Year)		Code (Instr. 8)		on 4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		ed of (D) Beneficially	of Securities ly Owned Following Fransaction(s) ad 4)		6. Owner: Form: Direct or Indi	ship Indire Bene (D) Own	ficial ership	
							de	V	Amount	or	Price				(I) (Instr.	,	+)
Common	Stock		09/28/2015			S	S		13,100	D	\$ 2.169 (1)	1,129,268	,129,268		I	I By Lim	
Common	Stock		09/28/2015			S	S		10,000	D	\$ 2.65 (1)	1,119,268			I	-	Limited nerships
Common	Stock		09/29/2015			S	S		1,701 (2) (3)	D	\$ 2.15 (1)	1,117,567	(2) (3)		I (2) (3	-	Limited nerships 3)
Reminder: indirectly.	Report on a	separate lin	e for each class of se	ecurities be	neficial	ly owne	ed dir	ectly	or								
j								со	ntained	in th	is form	to the colle are not req rrently valid	uired to re	espond	unless		02)
			Table II	- Derivativ (e.g., put								cially Owned	ĺ				
(Instr. 3)	Conversion	(Month/Day/Year) any		Date, if C	4. Transaction Code Year) (Instr. 8)							7. Title and Amount of Jnderlying Securities Instr. 3 and	8. Price of Derivative Security (Instr. 5)		ive les lially ling led etion(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Benefic Owners (Instr. 4
						.,	- 										

Post Company (Addition	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
AWM Investment Company, Inc. 527 MADISON AVENUE SUITE 2600 NEW YORK, NY 10022		X					

Signatures

Adam Stettner	09/30/2015
**Signature of Reporting	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This is a weighted average price.
 - AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Fund III QP, L.P. (SSFQP), Special Situations Cayman
- Fund, L.P. (CAYMAN) and Special Situations Life Sciences Fund, L.P. (SSLS and together with SSFQP and CAYMAN, the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 527,707 shares of Common Stock of the Issuer (the Shares) held by SSFQP, 175,902 Shares held by CAYMAN and 413,958 Shares held by SSLS.
- Austin W. Marxe (Marxe), David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are the controlling principals of AWM. The reporting person disclaims (3) beneficial ownership of the Shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.